|
C. Boyd Clarke has been a Director of QLT since 2003 and was apppointed as Chairman of the Board in February 2006. In March 2002, Mr. Clarke was President and Chief Executive Officer of Neose Technologies, Inc., a U.S. publicly listed biotechnology company focused on the development of protein therapeutics. Mr. Clarke resigned as Chairman and Chief Executive Officer of Neose effective May 4, 2006. Since 2002, Mr. Clarke has been on the board of directors of Neose and will remain on the Neose board until its annual meeting in May 2007. From December 1999 through March 2002, Mr. Clarke was President and Chief Executive Officer of Aviron, Inc., a biotechnology company developing vaccines, which was acquired by MedImmune, Inc., and was also Chairman from January 2001 through March 2002. From 1998 through 1999, Mr. Clarke was Chief Executive Officer and President of U.S. Bioscience, Inc., also a biotechnology company focused on products to treat cancer, which was also acquired by MedImmune. Mr Clarke served as President and Chief Operating Officer of U.S. Bioscience, Inc. from 1996 to 1998. From 1977 to 1996, Mr. Clarke held a number of positions at Merck & Co., Inc., including being the first President of Pasteur-Merieux MSD, and most recently as Vice President of Merck Vaccines. Mr. Clarke was formerly a director of the Biotechnology Industry Association. He is also a director of Rib-X Pharmaceuticals (a biotechnology company). Mr. Clarke has a Bachelor of Science in biochemistry and a Masters of Arts in History from the University of Calgary. | 